Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of "Moderate Buy" from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $43.60.

A number of research analysts have weighed in on COLL shares. Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a report on Friday, January 10th. Piper Sandler lowered their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the sale, the executive vice president now owns 154,204 shares of the company's stock, valued at $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 93,567 shares of company stock worth $2,774,710. Insiders own 3.98% of the company's stock.

Remove Ads

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently modified their holdings of COLL. Invesco Ltd. lifted its position in Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after buying an additional 289,335 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after purchasing an additional 64,958 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Collegium Pharmaceutical by 0.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after purchasing an additional 5,480 shares during the last quarter. Geode Capital Management LLC raised its position in Collegium Pharmaceutical by 0.7% in the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock valued at $29,974,000 after purchasing an additional 5,464 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in Collegium Pharmaceutical by 17.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company's stock worth $29,586,000 after purchasing an additional 116,327 shares in the last quarter.

Collegium Pharmaceutical Price Performance

COLL traded down $0.89 during midday trading on Tuesday, hitting $28.91. 382,217 shares of the company traded hands, compared to its average volume of 422,334. The business has a 50 day simple moving average of $30.78 and a two-hundred day simple moving average of $33.28. Collegium Pharmaceutical has a 52-week low of $27.28 and a 52-week high of $42.29. The company has a market capitalization of $910.26 million, a price-to-earnings ratio of 12.46 and a beta of 0.99. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, equities analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.